Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy

被引：0
|
作者：
Faruk Tas
Senem Karabulut
Rumeysa Ciftci
Fatma Sen
Burak Sakar
Rian Disci
Derya Duranyildiz
机构：
[1] Istanbul University,Institute of Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 73卷
关键词：
LDH; CEA; CA19-9; Metastatic; Pancreatic cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1163 / 1171
页数：8
相关论文
共 50 条
  • [41] Colonization of bile with gammaproteobacteria reduces survival after surgery for pancreatic cancer in patients receiving gemcitabine-based adjuvant chemotherapy
    Terry, Charlotte
    Halle-Smith, James
    Sutcliffe, Robert
    Marudanayagam, Ravi
    Chatzizacharias, Nikolaos
    Dasari, Bobby
    Bartlett, David
    Raza, Syed
    Roberts, Keith
    BRITISH JOURNAL OF SURGERY, 2024, 111
  • [42] Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer
    Jin Moriyama
    Yoko Oshima
    Tatsuki Nanami
    Takashi Suzuki
    Satoshi Yajima
    Fumiaki Shiratori
    Kimihiko Funahashi
    Hideaki Shimada
    Surgery Today, 2021, 51 : 1638 - 1648
  • [43] Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer
    A H Ko
    J Hwang
    A P Venook
    J L Abbruzzese
    E K Bergsland
    M A Tempero
    British Journal of Cancer, 2005, 93 : 195 - 199
  • [44] Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer
    Ko, AH
    Hwang, J
    Venook, AP
    Abbruzzese, JL
    Bergsland, EK
    Tempero, MA
    BRITISH JOURNAL OF CANCER, 2005, 93 (02) : 195 - 199
  • [45] CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy
    Heilbrun, L. K.
    Khanna, A.
    Venkatramanamoorthy, R.
    Shields, A. F.
    Philip, P. A.
    Zalupski, M. M.
    El-Rayes, B. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] CORRELATION BETWEEN TUMOR MARKERS (CEA AND CA19-9) AND RESPONSE TO SYSTEMIC CHEMOTHERAPY AND OVERALL SURVIVAL IN METASTATIC GASTRIC CANCER
    Aassab, Rachid
    Mesmoudi, Mohammed
    Khmamouche, Mohammed Reda
    M'rabti, Hind
    Errihani, Hassan
    ANNALS OF ONCOLOGY, 2011, 22 : v42 - v42
  • [47] Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
    Kim, Young Choon
    Kim, Hong Joo
    Park, Jung Ho
    Park, Dong Il
    Cho, Yong Kyun
    Sohn, Chong Il
    Jeon, Woo Kyu
    Kim, Byung Ik
    Shin, Jun Ho
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (12) : 1869 - 1875
  • [48] A clinical study of colorectal cancer patients associated with the serum CEA and CA19-9
    Horie, T.
    ANNALS OF ONCOLOGY, 2007, 18 : VII78 - VII78
  • [49] Prognostic impact of the ratio of preoperative CA19-9 to liver enzyme levels in pancreatic cancer patients with jaundice (predictability of combined CA19-9/AST and CA19-9/γ-GGT for jaundiced PDAC patients)
    Huang, Xumin
    Lu, Zipeng
    Zhang, Kai
    Wang, Guangfu
    Cai, Baobao
    Wu, Pengfei
    Yin, Jie
    Miao, Yi
    Jiang, Kuirong
    PANCREATOLOGY, 2021, 21 (06) : 1092 - 1101
  • [50] The Advancement Stage of Gastric Cancer and the Levels of CEA and Ca19-9 in Serum and Peritoneal Lavage
    Bak, Michal
    Wojciech, Magdalena
    Pielech, Adrianna
    Holka, Sylwia
    Zawadzki, Marek
    Murawa, Dawid
    BIOMEDICINES, 2024, 12 (11)
12345